For help on how to get the results you want, see our search tips.
2528 results
Medicine
Opinions on medicines for use outside EU Remove Opinions on medicines for use outside EU filter
Paediatric investigation plans Remove Paediatric investigation plans filter
Categories
Human Remove Human filter
-
List item
Opinion/decision on a Paediatric investigation plan (PIP): Stivarga, regorafenib (updated)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Oncology
PIP number: EMEA-001178-PIP01-11-M06, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet, Granules
Decision date: 03/12/2021, Last updated: 16/03/2023, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Praluent, Alirocumab (updated)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Endocrinology, -gynacology-fertility-metabolism
PIP number: EMEA-001169-PIP01-11-M05, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Solution for injection
Decision date: 31/12/2021, Last updated: 16/03/2023, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Veyvondi, vonicog alfa (updated)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Haematology-Hemostaseology
PIP number: EMEA-001164-PIP01-11-M05, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Powder and solvent for solution for injection
Decision date: 03/12/2021, Last updated: 16/03/2023, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Moventig, Naloxegol (updated)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Gastroentology-Hepatology
PIP number: EMEA-001146-PIP01-11-M07, Route(s) of administration: Oral use, Pharmaceutical form(s): Tablet, Age-appropriate oral liquid dosage formulation
Decision date: 03/12/2021, Last updated: 16/03/2023, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Evenity, Romosozumab (updated)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Endocrinology, -gynacology-fertility-metabolism
PIP number: EMEA-001075-PIP04-15-M04, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Solution for injection
Decision date: 31/12/2021, Last updated: 16/03/2023, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Opsumit, Macitentan (updated)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Cardiovascular diseases
PIP number: EMEA-001032-PIP01-10-M04, Route(s) of administration: Oral use, Pharmaceutical form(s): Dispersible tablet, Film-coated tablet
Decision date: 03/12/2021, Last updated: 16/03/2023, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Jakavi, Ruxolitinib (phosphate) (updated)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Oncology
PIP number: EMEA-000901-PIP04-17-M02, Route(s) of administration: Oral use, Gastric use, Pharmaceutical form(s): Tablet, Age-appropriate oral solid dosage form
Decision date: 03/12/2021, Last updated: 15/03/2023, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Fycompa, perampanel (updated)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Neurology
PIP number: EMEA-000467-PIP01-08-M15, Route(s) of administration: Oral use, Pharmaceutical form(s): Tablet, Oral suspension
Decision date: 03/12/2021, Last updated: 15/03/2023, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Bilastine (updated)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Ophthalmology
PIP number: EMEA-000347-PIP02-16-M03, Route(s) of administration: Ocular use, Pharmaceutical form(s): Eye drops, solution
Decision date: 03/12/2021, Last updated: 15/03/2023, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Methoxyflurane (updated)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Pain
PIP number: EMEA-000334-PIP01-08-M10, Route(s) of administration: Inhalation use, Pharmaceutical form(s): Inhalation vapour, liquid
Decision date: 03/12/2021, Last updated: 15/03/2023, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Xydalba, dalbavancin hydrochloride (updated)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Infectious diseases
PIP number: EMEA-000016-PIP01-07-M08, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Powder for concentrate for solution for infusion
Decision date: 03/12/2021, Last updated: 14/03/2023, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Loncastuximab tesirine (updated)
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Oncology
PIP number: EMEA-002665-PIP02-20, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Powder for concentrate for solution for infusion
Decision date: 01/10/2021, Last updated: 14/03/2023, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Tamiflu, Oseltamivir (phosphate) (updated)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Infectious diseases
PIP number: EMEA-000365-PIP01-08-M12, Route(s) of administration: Oral use, Pharmaceutical form(s): Capsule, hard, Powder for oral suspension
Decision date: 25/06/2021, Last updated: 13/03/2023, Compliance check: V, 15/10/2021 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Brilique, ticagrelor (updated)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Cardiovascular diseases; Haematology-Hemostaseology
PIP number: EMEA-000480-PIP01-08-M14, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet, Orodispersible tablet, Tablet
Decision date: 09/04/2021, Last updated: 13/03/2023, Compliance check: V, 25/06/2021 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Eylea, aflibercept (updated)
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Ophthalmology
PIP number: EMEA-000236-PIP05-18, Route(s) of administration: Intravitreal use, Pharmaceutical form(s): Solution for injection
Decision date: 04/04/2019, Last updated: 13/03/2023, Compliance check: V, 15/10/2021 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Cosentyx, Secukinumab (updated)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Immunology-Rheumatology-Transplantation
PIP number: EMEA-000380-PIP01-08-M04, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Powder for solution for injection, Solution for injection
Decision date: 01/12/2017, Last updated: 13/03/2023, Compliance check: V, 20/04/2021 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Cosentyx, Secukinumab (updated)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Immunology-Rheumatology-Transplantation
PIP number: EMEA-000380-PIP02-09-M04, Route(s) of administration: Subcutaneous use, Intravenous use, Pharmaceutical form(s): Powder for solution for injection or infusion, Solution for injection
Decision date: 07/12/2018, Last updated: 13/03/2023, Compliance check: V, 25/06/2021 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Tivicay, Dolutegravir (DTG) (updated)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Infectious diseases
PIP number: EMEA-000409-PIP01-08-M06, Route(s) of administration: Oral use, Pharmaceutical form(s): Age appropriate formulation for oral use, Film-coated tablet
Decision date: 09/07/2021, Last updated: 13/03/2023, Compliance check: V, 15/10/2021 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Elonva, corifollitropin alfa (updated)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Endocrinology, -gynacology-fertility-metabolism
PIP number: EMEA-000306-PIP01-08-M04, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Solution for injection
Decision date: 17/04/2019, Last updated: 13/03/2023, Compliance check: V, 29/01/2021 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Afstyla, lonoctocog alfa (updated)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Haematology-Hemostaseology
PIP number: EMEA-001215-PIP01-11-M07, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Powder and solvent for solution for injection
Decision date: 10/09/2019, Last updated: 10/03/2023, Compliance check: V, 10/09/2021 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): cerliponase alfa (updated)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Neurology
PIP number: EMEA-001362-PIP01-12-M03, Route(s) of administration: Intracerebral use, Pharmaceutical form(s): Concentrate for solution for infusion
Decision date: 05/09/2016, Last updated: 10/03/2023, Compliance check: V, 26/02/2021 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Turoctocog alfa pegol (updated)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Haematology-Hemostaseology
PIP number: EMEA-001174-PIP02-12-M02, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Powder and solvent for solution for injection
Decision date: 07/06/2017, Last updated: 10/03/2023, Compliance check: V, 23/07/2021 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Revestive, teduglutide (updated)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Gastroentology-Hepatology
PIP number: EMEA-000482-PIP01-08-M06, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Powder and solvent for solution for injection
Decision date: 01/12/2020, Last updated: 10/03/2023, Compliance check: V, 26/03/2021 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): citric acid (as citric acid anhydrous), macrogol 4000, potassium chloride, simeticone, sodium chloride, sodium citrate, sodium sulfate (as sodium sulfate anhydrous) (updated)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Gastroentology-Hepatology
PIP number: EMEA-001356-PIP02-12-M04, Route(s) of administration: Oral use, Pharmaceutical form(s): Powder for oral suspension
Decision date: 14/04/2021, Last updated: 10/03/2023, Compliance check: V, 17/12/2021 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Opdivo, nivolumab (updated)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Oncology
PIP number: EMEA-001407-PIP01-12-M03, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Concentrate for solution for infusion
Decision date: 05/11/2020, Last updated: 10/03/2023, Compliance check: V, 21/01/2022